Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

(2020) Dhivya R. Sudhan et al.   CANCER CELL

Landscape and function of multiple mutations within individual oncogenes

(2020) Yuki Saito et al.   NATURE

Phase and context shape the function of composite oncogenic mutations

(2020) Alexander N. Gorelick et al.   NATURE

Macromolecular modeling and design in Rosetta: recent methods and frameworks

(2020) Julia Koehler Leman et al.   NATURE METHODS

Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers

(2020) Byoungsan Choi et al.   eLife

Assessing multiple score functions in Rosetta for drug discovery

(2020) Shannon T. Smith et al.   PLoS One

Prediction of Protein Mutational Free Energy: Benchmark and Sampling Improvements Increase Classification Accuracy

(2020) Brandon Frenz et al.   Frontiers in Bioengineering and Biotechnology

BCL::Conf: Improved Open-Source Knowledge-Based Conformation Sampling Using the Crystallography Open Database

(2020) Jeffrey Mendenhall et al.   Journal of Chemical Information and Modeling

HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment

(2019) Jiayao Li et al.   CELL CYCLE

Prevalence and role of HER2 mutations in cancer

(2019) Emiliano Cocco et al.   PHARMACOLOGY & THERAPEUTICS

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

(2019) Jacqulyne P. Robichaux et al.   CANCER CELL

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

(2019) Neil Vasan et al.   SCIENCE

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

(2019) Lillian M. Smyth et al.   Cancer Discovery

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

(2018) Sarika Jain et al.   BREAST CANCER RESEARCH AND TREATMENT

High-throughput functional evaluation of variants of unknown significance in ERBB2

(2018) Masaaki Nagano et al.   CLINICAL CANCER RESEARCH

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

(2018) Pedram Razavi et al.   CANCER CELL

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

(2018) David M. Hyman et al.   NATURE

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

(2018) Sarah Croessmann et al.   CLINICAL CANCER RESEARCH

In Cellulo Protein-mRNA Interaction Assay to Determine the Action of G-Quadruplex-Binding Molecules

(2018) Rodrigo Prado Martins et al.   MOLECULES

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies

(2018) Utthara Nayar et al.   NATURE GENETICS

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

(2018) Emiliano Cocco et al.   Science Signaling

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer

(2017) Mathilde Guerin et al.   EUROPEAN JOURNAL OF CANCER

An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer

(2017) Ariella B. Hanker et al.   Cancer Discovery

AACR Project GENIE: Powering Precision Medicine through an International Consortium

(2017)   Cancer Discovery

Genomic alterations of ERBB receptors in cancer: clinical implications

(2017) Rosalin Mishra et al.   Oncotarget

Protocols for Molecular Modeling with Rosetta3 and RosettaScripts

(2016) Brian J. Bender et al.   BIOCHEMISTRY

Genomic Characterization of Primary Invasive Lobular Breast Cancer

(2016) Christine Desmedt et al.   JOURNAL OF CLINICAL ONCOLOGY

ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast

(2016) Zheng Ping et al.   Oncotarget

ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas

(2016) Gabrielle Deniziaut et al.   Oncotarget

Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity

(2015) H. J. Jacobsen et al.   CLINICAL CANCER RESEARCH

Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer

(2015) Michael Kloth et al.   GUT

ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB

(2015) James A. Maier et al.   Journal of Chemical Theory and Computation

Fully Flexible Docking of Medium Sized Ligand Libraries with RosettaLigand

(2015) Samuel DeLuca et al.   PLoS One

HER2missense mutations have distinct effects on oncogenic signaling and migration

(2015) Daniel J. Zabransky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment

(2015) S. M. Kavuri et al.   Cancer Discovery

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

(2014) Carlos L. Arteaga et al.   CANCER CELL

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution

(2014) Peter Eirew et al.   NATURE

Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations

(2014) P. Littlefield et al.   Science Signaling

Oncogenic ERBB3 Mutations in Human Cancers

(2013) Bijay S. Jaiswal et al.   CANCER CELL

Relapsed Classic E-Cadherin (CDH1)-Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations

(2013) J. S. Ross et al.   CLINICAL CANCER RESEARCH

Carboxyl Group Footprinting Mass Spectrometry and Molecular Dynamics Identify Key Interactions in the HER2-HER3 Receptor Tyrosine Kinase Interface

(2013) Timothy S. Collier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data

(2013) Daniel R. Roe et al.   Journal of Chemical Theory and Computation

Small-molecule ligand docking into comparative models with Rosetta

(2013) Steven A Combs et al.   Nature Protocols

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

(2013) A. B. Hanker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

(2013) M. Red Brewer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High-Resolution Comparative Modeling with RosettaCM

(2013) Yifan Song et al.   STRUCTURE

MMPBSA.py: An Efficient Program for End-State Free Energy Calculations

(2012) Bill R. Miller et al.   Journal of Chemical Theory and Computation

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

(2012) H. Greulich et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors

(2012) Satoshi Sogabe et al.   ACS Medicinal Chemistry Letters

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

(2011) Kathleen Aertgeerts et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis

(2011) T Smirnova et al.   ONCOGENE

Simulating water with rigid non-polarizable models: a general perspective

(2011) Carlos Vega et al.   PHYSICAL CHEMISTRY CHEMICAL PHYSICS

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

(2011) A. Chakrabarty et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3

(2010) A Chakrabarty et al.   ONCOGENE

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL